ANI PHARMACEUTICALS INC
About ANI PHARMACEUTICALS INC
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $883.4M
- Net income
- $78.3M
- Total assets
- $1.4B
- Market cap
- $1.8B
- Operating margin
- 12.6%
- Net margin
- 8.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $883.4M
- Operating expenses
- $772.3M
- Operating income
- $111.1M
- Income tax
- $17.5M
- Net income
- $78.3M
- EPS (basic)
- $3.50
- EPS (diluted)
- $3.32
Balance sheet
- Total assets
- $1.4B
- Current assets
- $753.1M
- Total liabilities
- $899.7M
- Current liabilities
- $278.1M
- Shareholders’ equity
- $540.7M
Cash flow
- Operating cash flow
- $185.2M
- Investing cash flow
- -$34.3M
- Financing cash flow
- -$9.9M
- Net cash flow
- $140.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.8B
- P/E ratio
- 24.1
- EPS (diluted)
- $3.32
- Shares outstanding
- 23.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 1999
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $78.3M in FY2025.
- Revenue grew 309% from FY2021 to FY2025.
- Trading 19% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 24.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review ANI PHARMACEUTICALS INC.
Write a review
News about ANI PHARMACEUTICALS INC
News & sentiment via Polygon.io
